Cargando…

Chemotherapy-induced oral mucositis is associated with detrimental bacterial dysbiosis

BACKGROUND: Gastrointestinal mucosal injury (mucositis), commonly affecting the oral cavity, is a clinically significant yet incompletely understood complication of cancer chemotherapy. Although antineoplastic cytotoxicity constitutes the primary injury trigger, the interaction of oral microbial com...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Bo-Young, Sobue, Takanori, Choquette, Linda, Dupuy, Amanda K., Thompson, Angela, Burleson, Joseph A., Salner, Andrew L., Schauer, Peter K., Joshi, Pujan, Fox, Evan, Shin, Dong-Guk, Weinstock, George M., Strausbaugh, Linda D., Dongari-Bagtzoglou, Anna, Peterson, Douglas E., Diaz, Patricia I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6482518/
https://www.ncbi.nlm.nih.gov/pubmed/31018870
http://dx.doi.org/10.1186/s40168-019-0679-5
_version_ 1783413897823256576
author Hong, Bo-Young
Sobue, Takanori
Choquette, Linda
Dupuy, Amanda K.
Thompson, Angela
Burleson, Joseph A.
Salner, Andrew L.
Schauer, Peter K.
Joshi, Pujan
Fox, Evan
Shin, Dong-Guk
Weinstock, George M.
Strausbaugh, Linda D.
Dongari-Bagtzoglou, Anna
Peterson, Douglas E.
Diaz, Patricia I.
author_facet Hong, Bo-Young
Sobue, Takanori
Choquette, Linda
Dupuy, Amanda K.
Thompson, Angela
Burleson, Joseph A.
Salner, Andrew L.
Schauer, Peter K.
Joshi, Pujan
Fox, Evan
Shin, Dong-Guk
Weinstock, George M.
Strausbaugh, Linda D.
Dongari-Bagtzoglou, Anna
Peterson, Douglas E.
Diaz, Patricia I.
author_sort Hong, Bo-Young
collection PubMed
description BACKGROUND: Gastrointestinal mucosal injury (mucositis), commonly affecting the oral cavity, is a clinically significant yet incompletely understood complication of cancer chemotherapy. Although antineoplastic cytotoxicity constitutes the primary injury trigger, the interaction of oral microbial commensals with mucosal tissues could modify the response. It is not clear, however, whether chemotherapy and its associated treatments affect oral microbial communities disrupting the homeostatic balance between resident microorganisms and the adjacent mucosa and if such alterations are associated with mucositis. To gain knowledge on the pathophysiology of oral mucositis, 49 subjects receiving 5-fluorouracil (5-FU) or doxorubicin-based chemotherapy were evaluated longitudinally during one cycle, assessing clinical outcomes, bacterial and fungal oral microbiome changes, and epithelial transcriptome responses. As a control for microbiome stability, 30 non-cancer subjects were longitudinally assessed. Through complementary in vitro assays, we also evaluated the antibacterial potential of 5-FU on oral microorganisms and the interaction of commensals with oral epithelial tissues. RESULTS: Oral mucositis severity was associated with 5-FU, increased salivary flow, and higher oral granulocyte counts. The oral bacteriome was disrupted during chemotherapy and while antibiotic and acid inhibitor intake contributed to these changes, bacteriome disruptions were also correlated with antineoplastics and independently and strongly associated with oral mucositis severity. Mucositis-associated bacteriome shifts included depletion of common health-associated commensals from the genera Streptococcus, Actinomyces, Gemella, Granulicatella, and Veillonella and enrichment of Gram-negative bacteria such as Fusobacterium nucleatum and Prevotella oris. Shifts could not be explained by a direct antibacterial effect of 5-FU, but rather resembled the inflammation-associated dysbiotic shifts seen in other oral conditions. Epithelial transcriptional responses during chemotherapy included upregulation of genes involved in innate immunity and apoptosis. Using a multilayer epithelial construct, we show mucositis-associated dysbiotic shifts may contribute to aggravate mucosal damage since the mucositis-depleted Streptococcus salivarius was tolerated as a commensal, while the mucositis-enriched F. nucleatum displayed pro-inflammatory and pro-apoptotic capacity. CONCLUSIONS: Altogether, our work reveals that chemotherapy-induced oral mucositis is associated with bacterial dysbiosis and demonstrates the potential for dysbiotic shifts to aggravate antineoplastic-induced epithelial injury. These findings suggest that control of oral bacterial dysbiosis could represent a novel preventive approach to ameliorate oral mucositis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40168-019-0679-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6482518
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-64825182019-05-02 Chemotherapy-induced oral mucositis is associated with detrimental bacterial dysbiosis Hong, Bo-Young Sobue, Takanori Choquette, Linda Dupuy, Amanda K. Thompson, Angela Burleson, Joseph A. Salner, Andrew L. Schauer, Peter K. Joshi, Pujan Fox, Evan Shin, Dong-Guk Weinstock, George M. Strausbaugh, Linda D. Dongari-Bagtzoglou, Anna Peterson, Douglas E. Diaz, Patricia I. Microbiome Research BACKGROUND: Gastrointestinal mucosal injury (mucositis), commonly affecting the oral cavity, is a clinically significant yet incompletely understood complication of cancer chemotherapy. Although antineoplastic cytotoxicity constitutes the primary injury trigger, the interaction of oral microbial commensals with mucosal tissues could modify the response. It is not clear, however, whether chemotherapy and its associated treatments affect oral microbial communities disrupting the homeostatic balance between resident microorganisms and the adjacent mucosa and if such alterations are associated with mucositis. To gain knowledge on the pathophysiology of oral mucositis, 49 subjects receiving 5-fluorouracil (5-FU) or doxorubicin-based chemotherapy were evaluated longitudinally during one cycle, assessing clinical outcomes, bacterial and fungal oral microbiome changes, and epithelial transcriptome responses. As a control for microbiome stability, 30 non-cancer subjects were longitudinally assessed. Through complementary in vitro assays, we also evaluated the antibacterial potential of 5-FU on oral microorganisms and the interaction of commensals with oral epithelial tissues. RESULTS: Oral mucositis severity was associated with 5-FU, increased salivary flow, and higher oral granulocyte counts. The oral bacteriome was disrupted during chemotherapy and while antibiotic and acid inhibitor intake contributed to these changes, bacteriome disruptions were also correlated with antineoplastics and independently and strongly associated with oral mucositis severity. Mucositis-associated bacteriome shifts included depletion of common health-associated commensals from the genera Streptococcus, Actinomyces, Gemella, Granulicatella, and Veillonella and enrichment of Gram-negative bacteria such as Fusobacterium nucleatum and Prevotella oris. Shifts could not be explained by a direct antibacterial effect of 5-FU, but rather resembled the inflammation-associated dysbiotic shifts seen in other oral conditions. Epithelial transcriptional responses during chemotherapy included upregulation of genes involved in innate immunity and apoptosis. Using a multilayer epithelial construct, we show mucositis-associated dysbiotic shifts may contribute to aggravate mucosal damage since the mucositis-depleted Streptococcus salivarius was tolerated as a commensal, while the mucositis-enriched F. nucleatum displayed pro-inflammatory and pro-apoptotic capacity. CONCLUSIONS: Altogether, our work reveals that chemotherapy-induced oral mucositis is associated with bacterial dysbiosis and demonstrates the potential for dysbiotic shifts to aggravate antineoplastic-induced epithelial injury. These findings suggest that control of oral bacterial dysbiosis could represent a novel preventive approach to ameliorate oral mucositis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40168-019-0679-5) contains supplementary material, which is available to authorized users. BioMed Central 2019-04-25 /pmc/articles/PMC6482518/ /pubmed/31018870 http://dx.doi.org/10.1186/s40168-019-0679-5 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Hong, Bo-Young
Sobue, Takanori
Choquette, Linda
Dupuy, Amanda K.
Thompson, Angela
Burleson, Joseph A.
Salner, Andrew L.
Schauer, Peter K.
Joshi, Pujan
Fox, Evan
Shin, Dong-Guk
Weinstock, George M.
Strausbaugh, Linda D.
Dongari-Bagtzoglou, Anna
Peterson, Douglas E.
Diaz, Patricia I.
Chemotherapy-induced oral mucositis is associated with detrimental bacterial dysbiosis
title Chemotherapy-induced oral mucositis is associated with detrimental bacterial dysbiosis
title_full Chemotherapy-induced oral mucositis is associated with detrimental bacterial dysbiosis
title_fullStr Chemotherapy-induced oral mucositis is associated with detrimental bacterial dysbiosis
title_full_unstemmed Chemotherapy-induced oral mucositis is associated with detrimental bacterial dysbiosis
title_short Chemotherapy-induced oral mucositis is associated with detrimental bacterial dysbiosis
title_sort chemotherapy-induced oral mucositis is associated with detrimental bacterial dysbiosis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6482518/
https://www.ncbi.nlm.nih.gov/pubmed/31018870
http://dx.doi.org/10.1186/s40168-019-0679-5
work_keys_str_mv AT hongboyoung chemotherapyinducedoralmucositisisassociatedwithdetrimentalbacterialdysbiosis
AT sobuetakanori chemotherapyinducedoralmucositisisassociatedwithdetrimentalbacterialdysbiosis
AT choquettelinda chemotherapyinducedoralmucositisisassociatedwithdetrimentalbacterialdysbiosis
AT dupuyamandak chemotherapyinducedoralmucositisisassociatedwithdetrimentalbacterialdysbiosis
AT thompsonangela chemotherapyinducedoralmucositisisassociatedwithdetrimentalbacterialdysbiosis
AT burlesonjosepha chemotherapyinducedoralmucositisisassociatedwithdetrimentalbacterialdysbiosis
AT salnerandrewl chemotherapyinducedoralmucositisisassociatedwithdetrimentalbacterialdysbiosis
AT schauerpeterk chemotherapyinducedoralmucositisisassociatedwithdetrimentalbacterialdysbiosis
AT joshipujan chemotherapyinducedoralmucositisisassociatedwithdetrimentalbacterialdysbiosis
AT foxevan chemotherapyinducedoralmucositisisassociatedwithdetrimentalbacterialdysbiosis
AT shindongguk chemotherapyinducedoralmucositisisassociatedwithdetrimentalbacterialdysbiosis
AT weinstockgeorgem chemotherapyinducedoralmucositisisassociatedwithdetrimentalbacterialdysbiosis
AT strausbaughlindad chemotherapyinducedoralmucositisisassociatedwithdetrimentalbacterialdysbiosis
AT dongaribagtzoglouanna chemotherapyinducedoralmucositisisassociatedwithdetrimentalbacterialdysbiosis
AT petersondouglase chemotherapyinducedoralmucositisisassociatedwithdetrimentalbacterialdysbiosis
AT diazpatriciai chemotherapyinducedoralmucositisisassociatedwithdetrimentalbacterialdysbiosis